PriceTargets.com logo

Baxter International - BAX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $40.91
  • Forecasted Upside: 25.37%
  • Number of Analysts: 11
  • Breakdown:
  • 1 Sell Ratings
  • 7 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$32.63 As of 11/20/2024 01:00 AM ET
▲ +0.11 (0.34%)

This chart shows the closing price for BAX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Baxter International Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BAX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BAX

Analyst Price Target is $40.91
▲ +25.37% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for Baxter International in the last 3 months. The average price target is $40.91, with a high forecast of $54.00 and a low forecast of $30.00. The average price target represents a 25.37% upside from the last price of $32.63.

This chart shows the closing price for BAX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 11 investment analysts is to hold stock in Baxter International. This rating has held steady since December 2022, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
8/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
10/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
11/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 7 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/11/2024Stifel NicolausLower TargetBuy ➝ Buy$46.00 ➝ $38.00
10/1/2024CitigroupBoost TargetNeutral ➝ Neutral$38.00 ➝ $40.00
8/8/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$36.00 ➝ $40.00
8/7/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$44.00 ➝ $42.00
8/7/2024Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$44.00 ➝ $40.00
7/15/2024Morgan StanleyDowngradeEqual Weight ➝ Underweight$39.00 ➝ $30.00
7/10/2024CitigroupLower TargetNeutral ➝ Neutral$38.00 ➝ $37.00
7/2/2024Evercore ISILower TargetOutperform ➝ Outperform$46.00 ➝ $45.00
5/30/2024The Goldman Sachs GroupInitiated CoverageNeutral$36.00
5/22/2024CitigroupLower TargetNeutral ➝ Neutral$44.00 ➝ $38.00
5/10/2024TD CowenDowngradeBuy ➝ Hold$40.00
4/3/2024CitigroupBoost TargetNeutral ➝ Neutral$41.00 ➝ $44.00
3/5/2024Bank of AmericaBoost TargetNeutral ➝ Neutral$42.00 ➝ $45.00
2/12/2024BarclaysBoost TargetOverweight ➝ Overweight$52.00 ➝ $54.00
2/9/2024JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$38.00 ➝ $44.00
2/6/2024UBS GroupLower TargetNeutral ➝ Neutral$40.00 ➝ $36.00
12/4/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$45.00 ➝ $39.00
10/31/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$49.00 ➝ $36.00
10/24/2023Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$35.00 ➝ $50.00
10/2/2023CitigroupLower Target$45.00 ➝ $41.00
8/21/2023CitigroupLower TargetNeutral ➝ Neutral$47.00 ➝ $45.00
7/31/2023KeyCorpLower TargetOverweight$53.00 ➝ $51.00
7/31/2023BarclaysLower TargetOverweight ➝ Overweight$58.00 ➝ $54.00
7/28/2023Wells Fargo & CompanyLower TargetEqual Weight$46.00 ➝ $44.00
7/12/2023Stifel NicolausBoost Target$54.00 ➝ $56.00
5/30/2023888Reiterated RatingAssumes
5/1/2023BarclaysBoost Target$54.00 ➝ $58.00
4/28/2023Stifel NicolausBoost Target$45.00 ➝ $54.00
4/28/2023Deutsche Bank AktiengesellschaftBoost Target$40.00 ➝ $50.00
4/28/2023KeyCorpBoost Target$52.00 ➝ $53.00
4/4/2023Evercore ISILower TargetOutperform$50.00 ➝ $48.00
3/28/2023UBS GroupInitiated CoverageNeutral$43.00
2/13/2023CitigroupLower TargetNeutral$58.00 ➝ $44.00
2/13/2023BarclaysLower TargetOverweight$63.00 ➝ $54.00
2/10/2023Wells Fargo & CompanyLower TargetEqual Weight$52.00 ➝ $43.00
2/10/2023Morgan StanleyLower TargetEqual Weight$55.00 ➝ $44.00
2/10/2023CowenLower TargetOutperform$70.00 ➝ $45.00
2/6/2023KeyCorpLower TargetOverweight$73.00 ➝ $60.00
1/9/2023Wells Fargo & CompanyLower TargetEqual Weight$57.00 ➝ $52.00
1/6/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$55.00
1/5/2023Raymond JamesDowngradeOutperform ➝ Market Perform
1/4/2023BarclaysLower Target$64.00 ➝ $63.00
1/3/2023Bank of AmericaDowngradeBuy ➝ Neutral$66.00 ➝ $55.00
12/19/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$68.00 ➝ $55.00
12/15/2022Wells Fargo & CompanyLower TargetEqual Weight$59.00 ➝ $57.00
12/15/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$69.00 ➝ $51.00
12/12/2022CitigroupDowngradeBuy ➝ Neutral$64.00 ➝ $58.00
11/3/2022The Goldman Sachs GroupLower TargetSell$60.00 ➝ $53.00
10/28/2022Raymond JamesLower TargetOutperform$66.00 ➝ $61.00
10/28/2022Wells Fargo & CompanyLower TargetEqual Weight$63.00 ➝ $59.00
10/28/2022KeyCorpLower TargetOverweight$77.00 ➝ $73.00
10/17/2022BarclaysInitiated CoverageOverweight$64.00
10/12/2022Jefferies Financial GroupInitiated CoverageHold$62.00
10/11/2022Morgan StanleyLower TargetOverweight$72.00 ➝ $70.00
10/5/2022CitigroupLower Target$74.00 ➝ $70.00
8/3/2022The Goldman Sachs GroupReiterated RatingSell$70.00 ➝ $60.00
7/29/2022CowenLower Target$95.00 ➝ $70.00
7/29/2022CowenLower Target$95.00 ➝ $70.00
7/29/2022Deutsche Bank AktiengesellschaftLower Target$99.00 ➝ $69.00
7/29/2022Morgan StanleyLower TargetOverweight$86.00 ➝ $72.00
7/28/2022CitigroupLower Target$82.00 ➝ $74.00
7/18/2022Stifel NicolausLower Target$85.00 ➝ $75.00
7/15/2022Morgan StanleyLower TargetOverweight$95.00 ➝ $86.00
6/24/2022JPMorgan Chase & Co.Lower TargetOverweight$90.00 ➝ $78.00
6/24/2022Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$71.00
5/23/2022Morgan StanleyLower TargetOverweight$100.00 ➝ $95.00
5/17/2022CitigroupLower TargetBuy$98.00 ➝ $85.00
4/29/2022Raymond JamesLower Target$96.00 ➝ $85.00
4/4/2022The Goldman Sachs GroupDowngradeNeutral ➝ Sell$88.00 ➝ $77.00
3/1/2022Bank of AmericaInitiated CoverageBuy ➝ Buy$100.00
2/18/2022Wells Fargo & CompanyLower TargetOverweight$95.00 ➝ $93.00
2/18/2022Stifel NicolausBoost TargetBuy$90.00 ➝ $91.00
2/18/2022UBS GroupBoost TargetNeutral ➝ Neutral$88.00 ➝ $91.00
2/18/2022Morgan StanleyLower TargetOverweight$110.00 ➝ $105.00
2/18/2022Raymond JamesLower TargetOutperform$99.00 ➝ $96.00
2/18/2022KeyCorpLower TargetOverweight$98.00 ➝ $95.00
2/11/2022The Goldman Sachs GroupInitiated CoverageNeutral$91.00
1/7/2022CitigroupInitiated CoverageBuy$101.00
1/7/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$86.00 ➝ $110.00
1/4/2022Raymond JamesBoost TargetOutperform$93.00 ➝ $99.00
1/4/2022KeyCorpBoost TargetOverweight$92.00 ➝ $98.00
12/17/2021JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight
10/29/2021Morgan StanleyLower TargetEqual Weight$90.00 ➝ $86.00
9/21/2021Raymond JamesInitiated CoverageBuy$93.00
9/13/2021CowenUpgradeMarket Perform ➝ Outperform$98.00
9/5/2021Leerink PartnersReiterated RatingBuy
9/3/2021BarclaysUpgradeEqual Weight ➝ Overweight$93.00 ➝ $100.00
8/3/2021The Goldman Sachs GroupLower TargetNeutral$93.00 ➝ $80.00
8/2/2021KeyCorpLower TargetOverweight$94.00 ➝ $92.00
7/29/2021Stifel NicolausLower TargetBuy$95.00 ➝ $90.00
7/29/2021Piper SandlerLower TargetNeutral$85.00 ➝ $82.00
5/24/2021BarclaysInitiated CoverageEqual Weight$93.00
4/30/2021CitigroupBoost Target$94.00 ➝ $98.00
4/29/2021Piper SandlerBoost TargetNeutral ➝ In-Line$80.00 ➝ $85.00
3/18/2021OppenheimerReiterated RatingBuy
2/5/2021Credit Suisse GroupLower TargetOutperform$99.00 ➝ $95.00
2/5/2021Raymond JamesLower TargetOutperform$88.00 ➝ $85.00
1/29/2021Piper SandlerDowngradeOverweight ➝ Neutral$100.00 ➝ $80.00
1/6/2021UBS GroupDowngradeBuy ➝ Neutral$95.00 ➝ $85.00
12/15/2020Morgan StanleyBoost TargetEqual Weight$84.00 ➝ $90.00
12/15/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$96.00 ➝ $85.00
11/2/2020Stifel NicolausLower TargetBuy$90.00 ➝ $88.00
10/30/2020Morgan StanleyLower TargetEqual Weight$90.00 ➝ $84.00
10/30/2020KeyCorpLower TargetOverweight$98.00 ➝ $94.00
10/12/2020Raymond JamesLower TargetOutperform$95.00 ➝ $88.00
10/9/2020UBS GroupLower TargetBuy$98.00 ➝ $96.00
10/1/2020CitigroupUpgradeNeutral ➝ Buy$94.00
9/4/2020ArgusDowngradeBuy ➝ Hold
8/11/2020Credit Suisse GroupReiterated RatingBuy$99.00
7/31/2020Credit Suisse GroupReiterated RatingBuy$99.00
7/31/2020Raymond JamesLower TargetOutperform$97.00 ➝ $95.00
7/31/2020Morgan StanleyLower TargetEqual Weight$95.00 ➝ $90.00
7/30/2020OppenheimerReiterated RatingBuy
6/23/2020OppenheimerInitiated CoverageOutperform$100.00
5/1/2020UBS GroupBoost TargetBuy$95.00 ➝ $103.00
5/1/2020Leerink PartnersBoost TargetOutperform$96.00 ➝ $105.00
5/1/2020Credit Suisse GroupBoost TargetOutperform$97.00 ➝ $99.00
5/1/2020KeyCorpBoost TargetOverweight$92.00 ➝ $98.00
4/30/2020Piper SandlerBoost TargetOverweight$90.00 ➝ $100.00
4/28/2020JPMorgan Chase & Co.Boost TargetOverweight$94.00 ➝ $96.00
4/20/2020Wells Fargo & CompanyBoost TargetOverweight$92.00 ➝ $104.00
4/14/2020BarclaysReiterated RatingHold$84.00
4/13/2020Raymond JamesBoost TargetOutperform$90.00 ➝ $97.00
4/2/2020Wells Fargo & CompanyReiterated RatingBuy
3/27/2020Morgan StanleyBoost TargetHold$88.00 ➝ $95.00
3/19/2020Stifel NicolausUpgradeHold ➝ Buy$87.00 ➝ $95.00
3/18/2020Wells Fargo & CompanyLower Target$102.00 ➝ $95.00
3/18/2020Deutsche Bank AktiengesellschaftLower TargetBuy$109.00 ➝ $99.00
3/18/2020CitigroupLower TargetNeutral$94.00 ➝ $89.00
3/18/2020Credit Suisse GroupLower TargetOutperform$98.00 ➝ $96.00
3/18/2020Raymond JamesLower TargetNeutral ➝ Outperform$95.00 ➝ $90.00
3/18/2020KeyCorpUpgradeSector Weight ➝ Overweight$92.00
3/17/2020Leerink PartnersReiterated RatingOutperform
3/6/2020Credit Suisse GroupBoost TargetOutperform$95.00 ➝ $98.00
3/4/2020CitigroupInitiated CoverageNeutral$94.00
2/14/2020Wells Fargo & CompanyBoost TargetOverweight$100.00 ➝ $102.00
2/12/2020The Goldman Sachs GroupInitiated CoverageBuy$104.00
2/6/2020CfraBoost TargetHold$87.00 ➝ $93.00
1/16/2020Wells Fargo & CompanyBoost TargetOverweight$95.00 ➝ $100.00
1/13/2020UBS GroupReiterated RatingBuy$102.00
1/2/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight
1/2/2020CitigroupUpgradeNeutral ➝ Buy
1/2/2020Evercore ISIUpgradeIn-Line ➝ Outperform$80.00 ➝ $94.00
12/20/2019JPMorgan Chase & Co.Boost TargetOverweight$89.00 ➝ $94.00
12/17/2019Morgan StanleyDowngradeOverweight ➝ Equal Weight$90.00 ➝ $88.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 13 very positive mentions
  • 22 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
4/25/2024
  • 17 very positive mentions
  • 34 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/25/2024
  • 10 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
6/24/2024
  • 15 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 16 very positive mentions
  • 30 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 13 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/22/2024
  • 11 very positive mentions
  • 29 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
Mentions as of
10/22/2024
  • 15 very positive mentions
  • 31 positive mentions
  • 8 negative mentions
  • 2 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 15 very positive mentions
  • 31 positive mentions
  • 8 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Baxter International logo
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Read More

Today's Range

Now: $32.63
Low: $31.76
High: $32.67

50 Day Range

MA: $36.46
Low: $31.71
High: $40.26

52 Week Range

Now: $32.63
Low: $31.60
High: $44.01

Volume

6,309,152 shs

Average Volume

4,106,408 shs

Market Capitalization

$16.66 billion

P/E Ratio

163.16

Dividend Yield

3.51%

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Baxter International?

The following Wall Street research analysts have issued research reports on Baxter International in the last year: Bank of America Co., Barclays PLC, Citigroup Inc., Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Stifel Nicolaus, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for BAX.

What is the current price target for Baxter International?

0 Wall Street analysts have set twelve-month price targets for Baxter International in the last year. Their average twelve-month price target is $40.91, suggesting a possible upside of 25.4%. Barclays PLC has the highest price target set, predicting BAX will reach $54.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $30.00 for Baxter International in the next year.
View the latest price targets for BAX.

What is the current consensus analyst rating for Baxter International?

Baxter International currently has 1 sell rating, 7 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BAX, but not buy more shares or sell existing shares.
View the latest ratings for BAX.

What other companies compete with Baxter International?

Other companies that are similar to Baxter International include Becton, Dickinson and Company, Edwards Lifesciences, ResMed, IDEXX Laboratories and DexCom. Learn More about companies similar to Baxter International.

How do I contact Baxter International's investor relations team?

Baxter International's physical mailing address is One Baxter Parkway DF2-1W, Deerfield IL, 60015. The medical instruments supplier's listed phone number is (224) 948-2000 and its investor relations email address is [email protected]. The official website for Baxter International is www.baxter.com. Learn More about contacing Baxter International investor relations.